Alle Storys
Folgen
Keine Story von IsoTis OrthoBiologics mehr verpassen.

IsoTis OrthoBiologics

IsoTis Adjourns Special Meeting to October 23, 2007

Irvine, California (ots/PRNewswire)

IsoTis, Inc. (NASDAQ: ISOT)
("IsoTis"), an orthobiologics company, today announced that it has
adjourned the special meeting of stockholders it called to approve
the acquisition of IsoTis by Integra LifeSciences Holdings
Corporation (NASDAQ: IART) ("Integra") pursuant to an agreement and
plan of merger dated as of August 6, 2007.
The special meeting of stockholders was held at 9 a.m. Pacific
time today. An insufficient number of shares was present at the
meeting to establish the quorum necessary to approve the proposed
transaction. As a result, IsoTis determined to adjourn the meeting to
October 23, 2007 until 7.30 a.m. Pacific time to permit additional
time to collect the proxies necessary to establish a quorum and
approve the acquisition by Integra.
The vast majority of IsoTis' stockholder base resides outside the
United States of America, including thousands of retail stockholders,
and many of these shares have not been voted. The adjournment of the
meeting will provide these and other IsoTis stockholders additional
time to vote their shares.
The IsoTis Board of Directors continues to believe unanimously
that the interests of IsoTis' stockholders are best served by the
acquisition by Integra, and that there are no feasible alternatives
for the company and the stockholders.
If IsoTis is unable to obtain the vote necessary to approve
the proposed transaction, the company believes it will have to seek
bankruptcy protection.
About IsoTis
IsoTis is an orthobiologics company that develops, manufactures
and markets proprietary products for the treatment of musculoskeletal
diseases and disorders. IsoTis' current orthobiologics products are
bone graft substitutes that promote the regeneration of bone and are
used to repair natural, trauma-related and surgically-created defects
common in orthopedic procedures, including spinal fusions. IsoTis'
current commercial business is highlighted by its Accell line of
products, which the company believes represents the next generation
in bone graft substitution.
On August 7, 2007 Integra and IsoTis announced that they have
reached a definitive agreement to create a global orthobiologics
leader. The combination would create a comprehensive orthobiologics
portfolio, one of the largest sales organizations focused on
orthobiologics in the US, and multiple cross-selling opportunities.
The transaction is subject to approval of IsoTis' stockholders, as
well as other closing conditions and approvals. Upon closing, IsoTis
will become a wholly-owned subsidiary of Integra and Integra will be
one of the largest companies in the world focused on advanced
technology in orthobiologics.
Forward-Looking Statements
Certain statements in this press release are "forward-looking
statements" within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, including those that refer to
management's plans and expectations for, among other things, future
operations, strategies, prospects, performance and financial
condition and IsoTis' proposed acquisition by Integra. Words such as
"strategy," "expects," "plans," "anticipates," "believes," "may,"
"will," "might," "could," "would," "continues," "estimates,"
"intends," "pursues," "projects," "goals," "targets" or the negative
or other variations thereof and other words of similar meaning are
intended to identify such forward-looking statements. One can also
identify them by the fact that they do not relate strictly to
historical or current facts. Such statements are based on the current
expectations and projections of the management of IsoTis only. Undue
reliance should not be placed on these statements because, by their
nature, they are subject to known and unknown risks and can be
affected by factors that are beyond the control of IsoTis. Actual
results could differ materially from current expectations and
projections. Any forward-looking statements are made pursuant to the
Private Securities Litigation Reform Act of 1995 and, as such, speak
only as of the date made. IsoTis undertakes no obligation to publicly
update any forward-looking statements, whether as a result of new
information, future events or otherwise.
A special stockholder meeting was held on October 11, 2007 to
obtain stockholder approval of the proposed transaction. This meeting
has been adjourned to October 23, 2007. IsoTis has filed with the
Securities and Exchange Commission and distributed to its
stockholders a definitive proxy statement and other relevant
documents in connection with the special stockholder meeting for the
proposed transaction. IsoTis stockholders are urged to read the
definitive proxy statement and other relevant materials because they
contain important information about IsoTis, Integra and the proposed
transaction. Investors may obtain a free copy of these materials and
other documents filed by IsoTis with the Securities and Exchange
Commission at the SEC's website at http://www.sec.gov, at IsoTis'
website at http://www.isotis.com or by sending a written request to
IsoTis at 2 Goodyear, Irvine, California 92618, Attention: Chief
Financial Officer.
IsoTis and its directors, executive officers and certain other
members of management and employees may be deemed to be participants
in soliciting proxies from its stockholders in favor of the proposed
merger. Information regarding the persons who may, under the rules of
the SEC, be considered to be participants in the solicitation of
IsoTis' stockholders in connection with the proposed transaction is
set forth in IsoTis' definitive proxy statement for its special
meeting. Additional information regarding these individuals and any
interest they have in the proposed transaction is set forth in the
definitive proxy statement on file with the SEC.

Contact:

For information contact: Rob Morocco, CFO, +1-949-855-7155,
robert.morocco@isotis.com; Hans Herklots, Director IR,
+1-949-855-7195 or +41-21-620-6011, hans.herklots@isotis.com

Weitere Storys: IsoTis OrthoBiologics
Weitere Storys: IsoTis OrthoBiologics
  • 19.09.2007 – 14:10

    IsoTis - Integra Merger

    Irvine, California (ots/PRNewswire) - - Leading Proxy Advisor Recommends Shareholders Support Merger IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that Institutional Shareholder Services, ISS, a leading proxy advisor, recommends shareholders support the merger of IsoTis and Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra"). For every M&A analysis, ISS reviews publicly available information and evaluates ...

  • 05.09.2007 – 22:27

    IsoTis Files Definitive Proxy Statement

    Irvine, California (ots/PRNewswire) - - Special Stockholders Meeting to Approve Merger With Integra on October 11, 2007 IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced the filing of a definitive proxy statement with the U.S. Securities and Exchange Commission ("SEC") in connection with the IsoTis-Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") combination. ...

  • 20.08.2007 – 14:31

    IsoTis Receives FDA Clearance for Accell Family of Products

    Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that it received a letter dated August 15, 2007 from the US Food and Drug Administration ("FDA"), clearing the Accell Family of Products for marketing in the US as Class II medical devices. The Accell Family of Products includes Accell 100, Accell Connexus and Accell Total Bone Matrix, as well as ...